250 related articles for article (PubMed ID: 18472959)
21. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
[TBL] [Abstract][Full Text] [Related]
24. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
25. PKC-mediated secretion of death factors in LNCaP prostate cancer cells is regulated by androgens.
Xiao L; Gonzalez-Guerrico A; Kazanietz MG
Mol Carcinog; 2009 Mar; 48(3):187-195. PubMed ID: 18756441
[TBL] [Abstract][Full Text] [Related]
26. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
27. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
[TBL] [Abstract][Full Text] [Related]
28. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
29. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
[TBL] [Abstract][Full Text] [Related]
30. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
31. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
32. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
33. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
34. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways.
Sadar MD
J Biol Chem; 1999 Mar; 274(12):7777-83. PubMed ID: 10075669
[TBL] [Abstract][Full Text] [Related]
35. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.
Rosenblatt AE; Burnstein KL
Mol Endocrinol; 2009 Mar; 23(3):412-21. PubMed ID: 19131511
[TBL] [Abstract][Full Text] [Related]
37. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
39. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Jin F; Fondell JD
Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
[TBL] [Abstract][Full Text] [Related]
40. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
